| Citation: |
Society of Gynecologic Oncology, Chinese Medical Association, Branch of Colposcopy and Cervical Pathology, China Healthy Birth Science Association, Professional Committee on Cancer Prevention and Control, Chinese Preventive Medicine Association, Specialized Committee on Cervical Cancer Prevention and Control Research, China Maternal and Child Health Research Association, National Collaborative Group for Cervical Cancer Prevention and Treatment, China Cancer Foundation, Committee on Cervical Cancer, China Anti-Cancer Association, Branch of Obstetric and Gynecological Health Medicine, China International Exchange and Promotive Association for Medical and Health Care. Preventive Human Papilloma Virus Vaccine Guidelines for Clinical Use in China(2025 edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 350-360. DOI: 10.12290/xhyxzz.2025-0246
|
Prophylactic human papilloma virus (HPV) vaccination is an effective strategy to prevent HPV infection and reduce the incidence of HPV-related diseases.Current clinical trials and real-world studies globally have demonstrated that prophylactic HPV vaccines are safe, immunogenic, and exhibit robust protective efficacy and effectiveness.Priority vaccination is recommended for females aged 9-26 years, with a focus on girls aged 9-14 years.Additionally, vaccination is advised for females aged 27-45 years and males aged 9-26 years to promote gender-neutral prevention strategies.Prophylactic HPV vaccination is also recommended for high-risk and special populations, including individuals with HPV infection or cytological abnormalities, those with a history of HPV-related lesions, genetically susceptible populations, individuals with high-risk lifestyle behaviors associated with cervical cancer, and immunocompromised patients.Regular cervical cancer screening remains essential post-vaccination.
| [1] |
中华医学会妇科肿瘤学分会, 中国优生科学协会阴道镜和宫颈病理学分会. 人乳头瘤病毒疫苗临床应用中国专家共识[J]. 中国妇产科临床杂志, 2021, 22(2): 225-234.
Gynecological Oncology Society of Chinese Medical Association, Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association. Chinese expert consensus on clinical application of human papillomavirus vaccine[J]. Chin J Clin Obstet Gynecol, 2021, 22(2): 225-234.
|
| [2] |
中华预防医学会疫苗与免疫分会. 子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识[J]. 中华预防医学杂志, 2019, 53(8): 761-803.
Vaccine and Immunization Branch, Chinese Preventive Medicine Association. Expert consensus on immunological prevention of human papillomavirus-related diseases[J]. Chin J Prev Med, 2019, 53(8): 761-803.
|
| [3] |
Chesson H W, Dunne E F, Hariri S, et al. The estimated lifetime probability of acquiring human papillomavirus in the United States[J]. Sex Transm Dis, 2014, 41(11): 660-664. DOI: 10.1097/OLQ.0000000000000193
|
| [4] |
WHO. Human papillomavirus vaccines: WHO position paper, December 2022[EB/OL]. (2022-12-16)[2024-12-05]. https://www.who.int/publications/i/item/who-wer9750-645-672
.
|
| [5] |
ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases report[EB/OL]. (2023-03-10)[2024-11-06]. https://hpvcentre.net/statistics/reports/XWX.pdf
.
|
| [6] |
Bruni L, Diaz M, Castellsagué X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings[J]. J Infect Dis, 2010, 202(12): 1789-1799. DOI: 10.1086/657321
|
| [7] |
Zeng Z Y, Austin R M, Wang L, et al. Nationwide prevalence and genotype distribution of high-risk human papillomavirus infection in China[J]. Am J Clin Pathol, 2022, 157(5): 718-723. DOI: 10.1093/ajcp/aqab181
|
| [8] |
Li K M, Li Q L, Song L, et al. The distribution and prevalence of human papillomavirus in women in mainland China[J]. Cancer, 2019, 125(7): 1030-1037. DOI: 10.1002/cncr.32003
|
| [9] |
Tao X, Zhang H N, Wang S N, et al. Prevalence and carcinogenic risk of high-risk human papillomavirus subtypes in different cervical cytology: a study of 124, 251 cases from the largest academic center in China[J]. J Am Soc Cytopathol, 2021, 10(4): 391-398. DOI: 10.1016/j.jasc.2021.03.006
|
| [10] |
Liao G D, Jiang X Y, She B, et al. Multi-infection patterns and co-infection preference of 27 human papillomavirus types among 137, 943 gynecological outpatients across China[J]. Front Oncol, 2020, 10: 449. DOI: 10.3389/fonc.2020.00449
|
| [11] |
Zhao F H, Lewkowitz A K, Hu S Y, et al. Prevalence of human papillomavirus and cervical intraepithelial neoplasia in China: a pooled analysis of 17 population-based studies[J]. Int J Cancer, 2012, 131(12): 2929-2938. DOI: 10.1002/ijc.27571
|
| [12] |
ICO/IARC Information Centre on HPV and Cancer. Statistics[EB/OL].[2024-10-17]. https://hpvcentre.net/datastatistics.php
.
|
| [13] |
Guan P, Howell-Jones R, Li N, et al. Human papillomavirus types in 115, 789 HPV-positive women: a meta-analysis from cervical infection to cancer[J]. Int J Cancer, 2012, 131(10): 2349-2359. DOI: 10.1002/ijc.27485
|
| [14] |
Zhang J Y, Cheng K Y, Wang Z L. Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China: a meta-analysis[J]. Arch Gynecol Obstet, 2020, 302(6): 1329-1337. DOI: 10.1007/s00404-020-05787-w
|
| [15] |
Bruni L, Albero G, Rowley J, et al. Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis[J]. Lancet Glob Health, 2023, 11(9): e1345-e1362. DOI: 10.1016/S2214-109X(23)00305-4
|
| [16] |
靳大川, 武淑芳, 郭师, 等. 我国男性HPV流行病学特征的描述性评价[J]. 医学研究杂志, 2018, 47(6): 104-108.
Jin D C, Wu S F, Guo S, et al. Epidemiological feature of human papillomavirus in Chinese male population: a descriptive study[J]. J Med Res, 2018, 47(6): 104-108.
|
| [17] |
Bogale A L, Belay N B, Medhin G, et al. Molecular epidemiology of human papillomavirus among HIV infected women in developing countries: systematic review and meta-analysis[J]. Virol J, 2020, 17(1): 179. DOI: 10.1186/s12985-020-01448-1
|
| [18] |
Duan R F, Zhang H Y, Wu A H, et al. Prevalence and risk factors for anogenital HPV infection and neoplasia among women living with HIV in China[J]. Sex Transm Infect, 2022, 98(4): 247-254.
|
| [19] |
Stelzle D, Tanaka L F, Lee K K, et al. Estimates of the global burden of cervical cancer associated with HIV[J]. Lancet Glob Health, 2021, 9(2): e161-e169. DOI: 10.1016/S2214-109X(20)30459-9
|
| [20] |
Wei F X, Gaisa M M, D'Souza G, et al. Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies[J]. Lancet HIV, 2021, 8(9): e531-e543. DOI: 10.1016/S2352-3018(21)00108-9
|
| [21] |
Farahmand M, Monavari S H, Tavakoli A. Prevalence and genotype distribution of human papillomavirus infection in different anatomical sites among men who have sex with men: a systematic review and meta-analysis[J]. Rev Med Virol, 2021, 31(6): e2219. DOI: 10.1002/rmv.2219
|
| [22] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. DOI: 10.3322/caac.21834
|
| [23] |
Han B F, Zheng R S, Zeng H M, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. DOI: 10.1016/j.jncc.2024.01.006
|
| [24] |
卫飞雪, 冯瑞梅, 高雪, 等. 1990—2019年全球宫颈癌疾病负担分析[J]. 中华肿瘤防治杂志, 2024, 31(4): 210-215.
Wei F X, Feng R M, Gao X, et al. Global burden of cervical cancer from 1990 to 2019[J]. Chin J Cancer Prev Treat, 2024, 31(4): 210-215.
|
| [25] |
De Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis[J]. Lancet Glob Health, 2020, 8(2): e180-e190. DOI: 10.1016/S2214-109X(19)30488-7
|
| [26] |
元玫雯, 王宏昊, 段如菲, 等. 2016年中国归因于人乳头瘤病毒感染的肿瘤发病与死亡分析[J]. 中华流行病学杂志, 2022, 43(5): 702-708.
Yuan M W, Wang H H, Duan R F, et al. Analysis on cancer incidence and mortality attributed to human papillomavirus infection in China, 2016[J]. Chin J Epidemiol, 2022, 43(5): 702-708.
|
| [27] |
Patel H, Wagner M, Singhal P, et al. Systematic review of the incidence and prevalence of genital warts[J]. BMC Infect Dis, 2013, 13: 39. DOI: 10.1186/1471-2334-13-39
|
| [28] |
Wei F X, Sheng W, Wu X, et al. Incidence of anogenital warts in Liuzhou, South China: a comparison of data from a prospective study and from the national surveillance system[J]. Emerg Microbes Infect, 2017, 6(12): e113.
|
| [29] |
Wilcox L J, Hull B P, Baldassari C M, et al. Diagnosis and management of recurrent respiratory papillomatosis[J]. Pediatr Infect Dis J, 2014, 33(12): 1283-1284. DOI: 10.1097/INF.0000000000000551
|
| [30] |
王临虹, 赵更力. 子宫颈癌综合防控指南[M]. 第2版. 北京: 人民卫生出版社, 2023.
Wang L H, Zhao G L. Guideline for comprehensive prevention and control of cervical cancer[M]. 2nd ed. Beijing: People's Medical Publishing House, 2023.
|
| [31] |
国家药品监督管理局药品审评中心. 国家药监局药审中心关于发布《人乳头瘤病毒疫苗临床试验技术指导原则(试行)》的通告(2023年第40号)[EB/OL]. (2023-07-10)[2023-07-10]. https://www.cde.org.cn/main/news/viewInfoCommon/f1623a35ec967425dd37b2bb8bcac3b5
.
Center for Drug Evaluation, NMPA. Notice of the Drug Evaluation Center of the National Medical Products Administration on issuing the technical guidelines for clinical trials of human papillomavirus vaccines (trial) (No. 40 of 2023)[EB/OL]. (2023-07-10)[2023-07-10]. https://www.cde.org.cn/main/news/viewInfoCommon/f1623a35ec967425dd37b2bb8bcac3b5
.
|
| [32] |
Shi L W, Li J, Yu B W, et al. Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females[J]. Hum Vaccin Immunother, 2023, 19(1): 2209001. DOI: 10.1080/21645515.2023.2209001
|
| [33] |
Hu Y M, Guo M, Li C G, et al. Immunogenicity noninferiority study of 2 doses and 3 doses of an Escherichia coli-produced HPV bivalent vaccine in girls vs. 3 doses in young women[J]. Sci China Life Sci, 2020, 63(4): 582-591. DOI: 10.1007/s11427-019-9547-7
|
| [34] |
Zhu F C, Li J, Hu Y M, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years[J]. Hum Vaccin Immunother, 2014, 10(7): 1795-1806.
|
| [35] |
Einstein M H, Takacs P, Chatterjee A, et al. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase Ⅲ randomized trial[J]. Hum Vaccin Immunother, 2014, 10(12): 3435-3445. DOI: 10.4161/hv.36121
|
| [36] |
Mariz F C, Gray P, Bender N, et al. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials[J]. Lancet Infect Dis, 2021, 21(10): 1458-1468. DOI: 10.1016/S1473-3099(20)30873-2
|
| [37] |
Li R C, Li Y P, Radley D, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, double-blind, placebo-controlled trial in Chinese males and females[J]. Vaccine, 2012, 30(28): 4284-4291. DOI: 10.1016/j.vaccine.2012.02.079
|
| [38] |
Hillman R J, Giuliano A R, Palefsky J M, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old[J]. Clin Vaccine Immunol, 2012, 19(2): 261-267. DOI: 10.1128/CVI.05208-11
|
| [39] |
Giuliano A R, Isaacs-Soriano K, Torres B N, et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--the MAM study[J]. Vaccine, 2015, 33(42): 5640-5646. DOI: 10.1016/j.vaccine.2015.08.072
|
| [40] |
Lyu H K, Wang S Y, Liang Z Z, et al. Immunogenicity and safety of the 9-valent human papillomavirus vaccine in Chinese females 9-45 years of age: a phase 3 open-label study[J]. Vaccine, 2022, 40(23): 3263-3271. DOI: 10.1016/j.vaccine.2022.02.061
|
| [41] |
Iversen O E, Miranda M J, Ulied A, et al. Immunogenicity of the 9-valent HPV vaccine using 2-dose regimens in girls and boys vs a 3-dose regimen in women[J]. JAMA, 2016, 316(22): 2411-2421. DOI: 10.1001/jama.2016.17615
|
| [42] |
Petersen L K, Restrepo J, Moreira E D, Jr, et al. Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase Ⅲ clinical trials[J]. Papillomavirus Res, 2017, 3: 105-115. DOI: 10.1016/j.pvr.2017.03.002
|
| [43] |
Qiao Y L, Wu T, Li R C, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus vaccine: an interim analysis of a randomized clinical trial[J]. J Natl Cancer Inst, 2020, 112(2): 145-153. DOI: 10.1093/jnci/djz074
|
| [44] |
Zhao F H, Wu T, Hu Y M, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial[J]. Lancet Infect Dis, 2022, 22(12): 1756-1768. DOI: 10.1016/S1473-3099(22)00435-2
|
| [45] |
Lehtinen M, Paavonen J, Wheeler C M, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial[J]. Lancet Oncol, 2012, 13(1): 89-99. DOI: 10.1016/S1470-2045(11)70286-8
|
| [46] |
Zhu F C, Hu S Y, Hong Y, et al. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: end-of-study results from a phase Ⅱ/Ⅲ, randomised, controlled trial[J]. Cancer Med, 2019, 8(14): 6195-6211. DOI: 10.1002/cam4.2399
|
| [47] |
Garland S M, Hernandez-Avila M, Wheeler C M, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases[J]. N Engl J Med, 2007, 356(19): 1928-1943. DOI: 10.1056/NEJMoa061760
|
| [48] |
Wei L H, Xie X, Liu J H, et al. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: a randomized, placebo-controlled trial with 78-month follow-up[J]. Vaccine, 2019, 37(27): 3617-3624. DOI: 10.1016/j.vaccine.2018.08.009
|
| [49] |
Giuliano A R, Palefsky J M, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males[J]. N Engl J Med, 2011, 364(5): 401-411. DOI: 10.1056/NEJMoa0909537
|
| [50] |
Huh W K, Joura E A, Giuliano A R, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial[J]. Lancet, 2017, 390(10108): 2143-2159. DOI: 10.1016/S0140-6736(17)31821-4
|
| [51] |
Garland S M, Pitisuttithum P, Ngan H Y S, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine: subgroup analysis of participants from Asian countries[J]. J Infect Dis, 2018, 218(1): 95-108. DOI: 10.1093/infdis/jiy133
|
| [52] |
Naud P S, Roteli-Martins C M, De Carvalho N S, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination[J]. Hum Vaccin Immunother, 2014, 10(8): 2147-2162. DOI: 10.4161/hv.29532
|
| [53] |
Porras C, Tsang S H, Herrero R, et al. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial[J]. Lancet Oncol, 2020, 21(12): 1643-1652. DOI: 10.1016/S1470-2045(20)30524-6
|
| [54] |
Kjaer S K, Nygård M, Sundström K, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries[J]. EClinicalMedicine, 2020, 23: 100401. DOI: 10.1016/j.eclinm.2020.100401
|
| [55] |
Zhao C, Zhao Y, Li J R, et al. The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age[J]. Hum Vaccin Immunother, 2022, 18(5): 2052700. DOI: 10.1080/21645515.2022.2052700
|
| [56] |
Goldstone S E, Giuliano A R, Palefsky J M, et al. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial[J]. Lancet Infect Dis, 2022, 22(3): 413-425. DOI: 10.1016/S1473-3099(21)00327-3
|
| [57] |
Restrepo J, Herrera T, Samakoses R, et al. Ten-year follow-up of 9-valent human papillomavirus vaccine: immunogenicity, effectiveness, and safety[J]. Pediatrics, 2023, 152(4): e2022060993. DOI: 10.1542/peds.2022-060993
|
| [58] |
Kjaer S K, Falkenthal T E H, Sundström K, et al. Long-term effectiveness of the nine-valent human papillomavirus vaccine: Interim results after 12 years of follow-up in Scandinavian women[J]. Hum Vaccin Immunother, 2024, 20(1): 2377903. DOI: 10.1080/21645515.2024.2377903
|
| [59] |
Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis[J]. Lancet, 2019, 394(10197): 497-509. DOI: 10.1016/S0140-6736(19)30298-3
|
| [60] |
Mesher D, Panwar K, Thomas S L, et al. The impact of the national HPV vaccination program in England using the bivalent HPV vaccine: surveillance of type-specific HPV in young females, 2010-2016[J]. J Infect Dis, 2018, 218(6): 911-921. DOI: 10.1093/infdis/jiy249
|
| [61] |
Rosenblum H G, Lewis R M, Gargano J W, et al. Declines in prevalence of human papillomavirus vaccine-type infection among females after introduction of vaccine-United States, 2003-2018[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(12): 415-420. DOI: 10.15585/mmwr.mm7012a2
|
| [62] |
Palmer T, Wallace L, Pollock K G, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study[J]. BMJ, 2019, 365: l1161.
|
| [63] |
Falcaro M, Soldan K, Ndlela B, et al. Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study[J]. BMJ, 2024, 385: e077341.
|
| [64] |
Palmer T J, Kavanagh K, Cuschieri K, et al. Invasive cervical cancer incidence following bivalent human papillomavirus vaccination: a population-based observational study of age at immunization, dose, and deprivation[J]. J Natl Cancer Inst, 2024, 116(6): 857-865. DOI: 10.1093/jnci/djad263
|
| [65] |
Lei J Y, Ploner A, Elfström K M, et al. HPV vaccination and the risk of invasive cervical cancer[J]. N Engl J Med, 2020, 383(14): 1340-1348. DOI: 10.1056/NEJMoa1917338
|
| [66] |
Tabibi T, Barnes J M, Shah A, et al. Human papillomavirus vaccination and trends in cervical cancer incidence and mortality in the US[J]. JAMA Pediatr, 2022, 176(3): 313-316. DOI: 10.1001/jamapediatrics.2021.4807
|
| [67] |
Muñoz-Quiles C, López-Lacort M, Díez-Domingo J, et al. Human papillomavirus vaccines effectiveness to prevent genital warts: a population-based study using health system integrated databases, 2009-2017[J]. Vaccine, 2022, 40(2): 316-324. DOI: 10.1016/j.vaccine.2021.11.062
|
| [68] |
Chow E P F, Carter A, Vickers T, et al. Effect on genital warts in Australian female and heterosexual male individuals after introduction of the national human papillomavirus gender-neutral vaccination programme: an analysis of national sentinel surveillance data from 2004-18[J]. Lancet Infect Dis, 2021, 21(12): 1747-1756. DOI: 10.1016/S1473-3099(21)00071-2
|
| [69] |
Nygård S, Nygård M, Orumaa M, et al. Quadrivalent HPV vaccine effectiveness against anogenital warts: a registry-based study of 2, 2 million individuals[J]. Vaccine, 2023, 41(37): 5469-5476. DOI: 10.1016/j.vaccine.2023.07.031
|
| [70] |
Meites E, Szilagyi P G, Chesson H W, et al. Human papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on Immunization Practices[J]. MMWR Morb Mortal Wkly Rep, 2019, 68(32): 698-702. DOI: 10.15585/mmwr.mm6832a3
|
| [71] |
Baker P, Kelly D, Medeiros R, et al. Eliminating HPV-caused cancers in Europe: achieving the possible[J]. J Cancer Policy, 2021, 28: 100280. DOI: 10.1016/j.jcpo.2021.100280
|
| [72] |
WHO, UNICEF. WHO/UNICEF HPV vaccine coverage estimates 2023 revision[EB/OL]. (2024-07-15)[2024-07-15]. https://cdn.who.int/media/docs/default-source/immunization/wuenic/notes-who-unicef-hpv-estimates-final-oct-2024.pdf?sfvrsn=9db8d3aa_1&download=true
.
|
| [73] |
Zhao F H, Tiggelaar S M, Hu S Y, et al. A multi-center survey of age of sexual debut and sexual behavior in Chinese women: suggestions for optimal age of human papillomavirus vaccination in China[J]. Cancer Epidemiol, 2012, 36(4): 384-390. DOI: 10.1016/j.canep.2012.01.009
|
| [74] |
Chen Q, Zhao H, Yao X M, et al. Comparing immunogenicity of the Escherichia coli-produced bivalent human papillomavirus vaccine in females of different ages[J]. Vaccine, 2020, 38(39): 6096-6102. DOI: 10.1016/j.vaccine.2020.07.030
|
| [75] |
Hu S Y, Xu X Q, Zhu F C, et al. Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial[J]. Hum Vaccin Immunother, 2021, 17(4): 955-964. DOI: 10.1080/21645515.2020.1829411
|
| [76] |
Szarewski A, Poppe W A J, Skinner S R, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18[J]. Int J Cancer, 2012, 131(1): 106-116. DOI: 10.1002/ijc.26362
|
| [77] |
Olsson S E, Kjaer S K, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection[J]. Hum Vaccin, 2009, 5(10): 696-704. DOI: 10.4161/hv.5.10.9515
|
| [78] |
Castellsagué X, Muñoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age[J]. Br J Cancer, 2011, 105(1): 28-37. DOI: 10.1038/bjc.2011.185
|
| [79] |
Giuliano A R, Joura E A, Garland S M, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population[J]. Gynecol Oncol, 2019, 154(1): 110-117. DOI: 10.1016/j.ygyno.2019.03.253
|
| [80] |
Sharpless K E, Marcus J Z, Kuroki L M, et al. ASCCP Committee opinion: adjuvant human papillomavirus vaccine for patients undergoing treatment for cervical intraepithelial neoplasia[J]. J Low Genit Tract Dis, 2023, 27(1): 93-96. DOI: 10.1097/LGT.0000000000000703
|
| [81] |
Kechagias K S, Kalliala I, Bowden S J, et al. Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis[J]. BMJ, 2022, 378: e070135.
|
| [82] |
Garland S M, Paavonen J, Jaisamrarn U, et al. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: post-hoc analysis from a randomized controlled trial[J]. Int J Cancer, 2016, 139(12): 2812-2826. DOI: 10.1002/ijc.30391
|
| [83] |
Pieralli A, Bianchi C, Auzzi N, et al. Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease[J]. Arch Gynecol Obstet, 2018, 298(6): 1205-1210. DOI: 10.1007/s00404-018-4926-y
|
| [84] |
Chen M, Li C, Cui Q L, et al. The efficacy of human papillomavirus prophylactic vaccination after conization in preventing cervical intraepithelial neoplasia recurrence: a prospective observational study in China[J]. Eur J Obstet Gynecol Reprod Biol, 2023, 286: 10-15. DOI: 10.1016/j.ejogrb.2023.04.014
|
| [85] |
Han L, Zhang B Y. Can prophylactic HPV vaccination reduce the recurrence of cervical lesions after surgery? Review and prospect[J]. Infect Agent Cancer, 2023, 18(1): 66. DOI: 10.1186/s13027-023-00547-2
|
| [86] |
Joura E A, Garland S M, Paavonen J, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data[J]. BMJ, 2012, 344: e1401. DOI: 10.1136/bmj.e1401
|
| [87] |
Ghelardi A, Marrai R, Bogani G, et al. Surgical treatment of vulvar HSIL: adjuvant HPV vaccine reduces recurrent disease[J]. Vaccines (Basel), 2021, 9(2): 83. DOI: 10.3390/vaccines9020083
|
| [88] |
Swedish K A, Factor S H, Goldstone S E. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study[J]. Clin Infect Dis, 2012, 54(7): 891-898. DOI: 10.1093/cid/cir1036
|
| [89] |
Deshmukh A A, Chhatwal J, Chiao E Y, et al. Long-term outcomes of adding HPV vaccine to the anal intraepithelial neoplasia treatment regimen in HIV-positive men who have sex with men[J]. Clin Infect Dis, 2015, 61(10): 1527-1535. DOI: 10.1093/cid/civ628
|
| [90] |
Mudry P, Vavrina M, Mazanek P, et al. Recurrent laryngeal papillomatosis: successful treatment with human papillomavirus vaccination[J]. Arch Dis Child, 2011, 96(5): 476-477. DOI: 10.1136/adc.2010.198184
|
| [91] |
Sullivan C, Curtis S, Mouzakes J. Therapeutic use of the HPV vaccine in Recurrent Respiratory Papillomatosis: a case report[J]. Int J Pediatr Otorhinolaryngol, 2017, 93: 103-106. DOI: 10.1016/j.ijporl.2016.12.035
|
| [92] |
Mauz P S, Schäfer F A, Iftner T, et al. HPV vaccination as preventive approach for recurrent respiratory papillomatosis - a 22-year retrospective clinical analysis[J]. BMC Infect Dis, 2018, 18(1): 343. DOI: 10.1186/s12879-018-3260-0
|
| [93] |
Magnusson P K, Lichtenstein P, Gyllensten U B. Heritability of cervical tumours[J]. Int J Cancer, 2000, 88(5): 698-701. DOI: 10.1002/1097-0215(20001201)88:5<698::AID-IJC3>3.0.CO;2-J
|
| [94] |
Shi Y Y, Li L, Hu Z B, et al. A genome-wide association study identifies two new cervical cancer susceptibility loci at 4q12 and 17q12[J]. Nat Genet, 2013, 45(8): 918-922. DOI: 10.1038/ng.2687
|
| [95] |
Seifert F, Eisenblätter R, Beckmann J, et al. Association of two genomic variants with HPV type-specific risk of cervical cancer[J]. Tumour Virus Res, 2023, 16: 200269. DOI: 10.1016/j.tvr.2023.200269
|
| [96] |
Kojic E M, Kang M, Cespedes M S, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women[J]. Clin Infect Dis, 2014, 59(1): 127-135. DOI: 10.1093/cid/ciu238
|
| [97] |
Staadegaard L, Rönn M M, Soni N, et al. Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: a systematic review and meta-analysis[J]. EClinicalMedicine, 2022, 52: 101585. DOI: 10.1016/j.eclinm.2022.101585
|
| [98] |
McClymont E, Lee M, Raboud J, et al. The efficacy of the quadrivalent human papillomavirus vaccine in girls and women living with human immunodeficiency virus[J]. Clin Infect Dis, 2019, 68(5): 788-794. DOI: 10.1093/cid/ciy575
|
| [99] |
Furer V, Rondaan C, Heijstek M, et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD[J]. RMD Open, 2019, 5(2): e001041. DOI: 10.1136/rmdopen-2019-001041
|
| [100] |
Mok C C, Ho L Y, Fong L S, et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study[J]. Ann Rheum Dis, 2013, 72(5): 659-664. DOI: 10.1136/annrheumdis-2012-201393
|
| [101] |
Mok C C, Ho L Y, To C H. Long-term immunogenicity of a quadrivalent human papillomavirus vaccine in systemic lupus erythematosus[J]. Vaccine, 2018, 36(23): 3301-3307. DOI: 10.1016/j.vaccine.2018.04.056
|
| [102] |
Grein I H R, Pinto N B F, Groot N, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study[J]. Pediatr Rheumatol Online J, 2020, 18(1): 87. DOI: 10.1186/s12969-020-00479-w
|
| [103] |
Jansen M H A, Rondaan C, Legger G E, et al. EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021[J]. Ann Rheum Dis, 2023, 82(1): 35-47. DOI: 10.1136/annrheumdis-2022-222574
|
| [104] |
中国疫苗行业协会免疫规划规范化管理与实践分会, 长三角免疫规划一体化项目工作组, 北京白求恩公益基金会. 中国成人风湿免疫性疾病患者疫苗接种专家共识(2023版)[J]. 中华预防医学杂志, 2024, 58(1): 1-10.
China Association for Vaccines, Affiliated Association for Standardized Management and Practice of Immunization Program, Working Group on Integration Project of Immunization Program in Yangtze River Delta, Beijing Bethune Charitable Foundation. Expert consensus on vaccinations in adult patients with autoimmune rheumatic diseases in China (2023 Edition)[J]. Chin J Prev Med, 2024, 58(1): 1-10.
|
| [105] |
Reinholdt K, Munk C, Thomsen L T, et al. Increased incidence of genital warts among women and men with type 1 diabetes compared with the general population-results from a nationwide registry-based, cohort study[J]. Acta Diabetol, 2022, 59(1): 105-112. DOI: 10.1007/s00592-021-01786-8
|
| [106] |
Prétet J L, Touzé A, Pazart L, et al. Anogenital distribution of mucosal HPV in males and females before and after renal transplantation[J]. Infect Dis Now, 2024, 54(1): 104830. DOI: 10.1016/j.idnow.2023.104830
|
| [107] |
Han J, Waller J L, Colombo R E, et al. Incidence and risk factors for HPV-associated cancers in women with end-stage renal disease[J]. J Investig Med, 2020, 68(5): 1002-1010. DOI: 10.1136/jim-2019-001262
|
| [108] |
Nelson D R, Neu A M, Abraham A, et al. Immunogenicity of human papillomavirus recombinant vaccine in children with CKD[J]. Clin J Am Soc Nephrol, 2016, 11(5): 776-784. DOI: 10.2215/CJN.09690915
|
| [109] |
Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2025[J]. JAAPA, 2025, 38(1): e40-e56.
|
| [110] |
Recommended adult immunization schedule for ages 19 years or older, United States, 2025[J]. JAAPA, 2025, 38(1): e25-e39.
|
| [111] |
Reinholdt K, Thomsen L T, Dehlendorff C, et al. Human papillomavirus-related anogenital premalignancies and cancer in renal transplant recipients: a Danish nationwide, registry-based cohort study[J]. Int J Cancer, 2020, 146(9): 2413-2422. DOI: 10.1002/ijc.32565
|
| [112] |
Kitano T, Schwartz K L, Abdulnoor M, et al. Immunogenicity of a quadrivalent human papillomavirus vaccine in pediatric kidney and liver transplant recipients[J]. Pediatr Transplant, 2023, 27(3): e14476. DOI: 10.1111/petr.14476
|
| [113] |
Boey L, Curinckx A, Roelants M, et al. Immunogenicity and safety of the 9-valent human papillomavirus vaccine in solid organ transplant recipients and adults infected with human immunodeficiency virus (HIV)[J]. Clin Infect Dis, 2021, 73(3): e661-e671. DOI: 10.1093/cid/ciaa1897
|
| [114] |
Stratton P, Battiwalla M, Tian X, et al. Immune response following quadrivalent human papillomavirus vaccination in women after hematopoietic allogeneic stem cell transplant: a nonrandomized clinical trial[J]. JAMA Oncol, 2020, 6(5): 696-705. DOI: 10.1001/jamaoncol.2019.6722
|
| [115] |
AST Infectious Diseases Community of Practice. Human papillomavirus infection in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13590. DOI: 10.1111/ctr.13590
|
| [116] |
Kamboj M, Bohlke K, Baptiste D M, et al. Vaccination of adults with cancer: ASCO guideline[J]. J Clin Oncol, 2024, 42(14): 1699-1721. DOI: 10.1200/JCO.24.00032
|
| [117] |
Yan X L, Li H Y, Song B, et al. Association of periconceptional or pregnancy exposure of HPV vaccination and adverse pregnancy outcomes: a systematic review and meta-analysis with trial sequential analysis[J]. Front Pharmacol, 2023, 14: 1181919. DOI: 10.3389/fphar.2023.1181919
|
| [118] |
Chen W, Zhao Y, Xie X, et al. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up[J]. Vaccine, 2019, 37(6): 889-897. DOI: 10.1016/j.vaccine.2018.12.030
|
| [119] |
Meng R G, Ma R, Wang J M, et al. Post-marketing surveillance for the safety of the 9-valent human papillomavirus vaccine: a retrospective real-world study in China[J]. Expert Rev Vaccines, 2023, 22(1): 696-703. DOI: 10.1080/14760584.2023.2239911
|
| [120] |
Global Advisory Committee on Vaccine Safety (GACVS). Safety of HPV vaccines[EB/OL]. (2017-07-14)[2024-12-23]. https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/human-papillomavirus-vaccines/safety
.
|
| [121] |
International Federation of Gynecology Obstetrics. Safety of HPV vaccination: a FIGO statement[J]. Int J Gynaecol Obstet, 2013, 123(3): 187-188. DOI: 10.1016/j.ijgo.2013.09.009
|
| [122] |
Zhao F H, Jastorff A, Hong Y, et al. Safety of AS04-HPV-16/18 vaccine in Chinese women aged 26 years and older and long-term protective effect in women vaccinated at age 18-25 years: a 10-year follow-up study[J]. Asia Pac J Clin Oncol, 2023, 19(4): 458-467. DOI: 10.1111/ajco.13833
|
| [123] |
张丽娜, 李克莉, 李燕, 等. 2017-2020年中国人乳头瘤病毒疫苗疑似预防接种异常反应监测[J]. 中国疫苗和免疫, 2023, 29(4): 451-457.
Zhang L N, Li K L, Li Y, et al. Surveillance for adverse events following immunization with human papillomavirus vaccines in China, 2017-2020[J]. Chin J Vaccin Immun, 2023, 29(4): 451-457.
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: